🚀 VC round data is live in beta, check it out!
Zoetis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zoetis and similar public comparables like UCB, Jiangsu Hengrui Pharma, Takeda Pharmaceuticals, CSL and more.
Zoetis Overview
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Founded
2012
HQ
Employees
14.5K
Website
Financials (LTM)
EV
$61B
Zoetis Financials
Zoetis reported last 12-month revenue of $10B and EBITDA of $4B.
In the same LTM period, Zoetis generated $7B in gross profit, $4B in EBITDA, and $3B in net income.
Revenue (LTM)
Zoetis P&L
In the most recent fiscal year, Zoetis reported revenue of $9B and EBITDA of $4B.
Zoetis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10B | XXX | $9B | XXX | XXX | XXX |
| Gross Profit | $7B | XXX | $7B | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $4B | XXX | $4B | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | 44% | XXX | XXX | XXX |
| EBIT Margin | 39% | XXX | 39% | XXX | XXX | XXX |
| Net Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Net Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | — | — | $7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zoetis Stock Performance
Zoetis has current market cap of $54B, and enterprise value of $61B.
Market Cap Evolution
Zoetis' stock price is $128.96.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $61B | $54B | 0.0% | XXX | XXX | XXX | $6.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZoetis Valuation Multiples
Zoetis trades at 6.4x EV/Revenue multiple, and 14.7x EV/EBITDA.
EV / Revenue (LTM)
Zoetis Financial Valuation Multiples
As of March 30, 2026, Zoetis has market cap of $54B and EV of $61B.
Equity research analysts estimate Zoetis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zoetis has a P/E ratio of 18.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $54B | XXX | $54B | XXX | XXX | XXX |
| EV (current) | $61B | XXX | $61B | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBITDA | 14.7x | XXX | 14.9x | XXX | XXX | XXX |
| EV/EBIT | 16.2x | XXX | 16.5x | XXX | XXX | XXX |
| EV/Gross Profit | 8.9x | XXX | 9.0x | XXX | XXX | XXX |
| P/E | 18.9x | XXX | 19.1x | XXX | XXX | XXX |
| EV/FCF | 24.2x | XXX | 24.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zoetis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zoetis Margins & Growth Rates
Zoetis' revenue in the last 12 month grew by 5%.
Zoetis' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.2M for the same period.
Zoetis' rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Zoetis' rule of X is 56% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Zoetis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zoetis Public Comps
See public comps and valuation multiples for other Pet Care and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| UCB | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Hengrui Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Takeda Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| argenx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zoetis M&A Activity
Zoetis acquired XXX companies to date.
Last acquisition by Zoetis was on XXXXXXXX, XXXXX. Zoetis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zoetis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZoetis Investment Activity
Zoetis invested in XXX companies to date.
Zoetis made its latest investment on XXXXXXXX, XXXXX. Zoetis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zoetis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zoetis
| When was Zoetis founded? | Zoetis was founded in 2012. |
| Where is Zoetis headquartered? | Zoetis is headquartered in United States. |
| How many employees does Zoetis have? | As of today, Zoetis has over 14K employees. |
| Who is the CEO of Zoetis? | Zoetis' CEO is Kristin C. Peck. |
| Is Zoetis publicly listed? | Yes, Zoetis is a public company listed on NYSE. |
| What is the stock symbol of Zoetis? | Zoetis trades under ZTS ticker. |
| When did Zoetis go public? | Zoetis went public in 2013. |
| Who are competitors of Zoetis? | Zoetis main competitors are UCB, Jiangsu Hengrui Pharma, Takeda Pharmaceuticals, CSL. |
| What is the current market cap of Zoetis? | Zoetis' current market cap is $54B. |
| What is the current revenue of Zoetis? | Zoetis' last 12 months revenue is $10B. |
| What is the current revenue growth of Zoetis? | Zoetis revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Zoetis? | Current revenue multiple of Zoetis is 6.4x. |
| Is Zoetis profitable? | Yes, Zoetis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Zoetis? | Zoetis' last 12 months EBITDA is $4B. |
| What is Zoetis' EBITDA margin? | Zoetis' last 12 months EBITDA margin is 44%. |
| What is the current EV/EBITDA multiple of Zoetis? | Current EBITDA multiple of Zoetis is 14.7x. |
| What is the current FCF of Zoetis? | Zoetis' last 12 months FCF is $3B. |
| What is Zoetis' FCF margin? | Zoetis' last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Zoetis? | Current FCF multiple of Zoetis is 24.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.